Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver DiseasesGuruFocus · Oct 11, 2026
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026GuruFocus · Sep 27, 2026This investment product is specifically engineered to mirror the U.S. dollar value of the Swedish Krona. It provides individual and professional investors with an easy and economical way to achieve investment benefits akin to holding the actual Swedish currency. Furthermore, the transactional costs for buying shares in this fund are intended to be no greater than those incurred when purchasing any other publicly traded equity securities.